The sympathetic nervous system in chronic kidney disease

Current Hypertension Reports

Volumn 15, Issue 4, 2013, Pages 370-376

  Ewen, Sebastian ^a   Ukena, Christian ^a   Linz, Dominik ^a   Schmieder, Roland E ^b   Böhm, Michael ^a   Mahfoud, Felix ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Ang II; Asymmetric dimethlyarginine (ADMA) related mechanisms; Chronic renal failure; CKD; Dialysis; Hypertension; Ischemia; Nitric oxide; NO; Oxidative stress; Pharmacotherapy; Renal denervation; Renal injury; Renalase; Sympathetic nervous system; Sympathetic overdrive

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ANGIOTENSIN II; CAPTOPRIL; CARVEDILOL; MOXONIDINE; N(G),N(G) DIMETHYLARGININE; RENALASE; TELMISARTAN; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CHEMORECEPTOR REFLEX; CHRONIC KIDNEY DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; EFFERENT NERVE; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY ISCHEMIA; MUSCLE SYMPATHETIC NERVE ACTIVITY; NERVE STIMULATION; NEUROMODULATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STOMACH SECRETION; SYMPATHETIC TONE;

ANIMALS; DENERVATION; HUMANS; HYPERTENSION; KIDNEY; NITRIC OXIDE; RENAL INSUFFICIENCY, CHRONIC; SYMPATHETIC NERVOUS SYSTEM;

EID: 84880920060     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0365-0     Document Type: Article

References (68)

1. •• Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380(9854):1649-61. doi: 10.1016/s0140-6736(12)61272-0. Important overwiev regarding the mortality of CK with and without hypertension.
2. Borrelli S, De Nicola L, Stanzione G, Conte G, Minutolo R. Resistant hypertension in nondialysis chronic kidney disease. Int J Hypertens. 2013;2013:1-8. doi: 10.1155/2013/929183.
3. Sarafidis PA, Li S, Chen SC, Collins AJ, Brown WW, Klag MJ, et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008;121(4):332-40. doi: 10.1016/j.amjmed.2007.11.025.
4. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340(17):1321-8. doi: 10.1056/NEJM199904293401704.
5. • Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M, Krum H. Sympatho-renal axis in chronic disease. Clin Res Cardiol. 2011;100(12):1049-57. doi: 10.1007/s00392-011-0335-y. Review article on the role of the sympathetic nervous system in different disease states and potential future indication of renal denervation.
6. DiBona GF. Neural control of the kidney: past, present, and future. Hypertension. 2003;41(3 Pt 2):621-4. doi: 10.1161/01.HYP.0000047205.52509.8A.
7. Buchner N, Vonend O, Rump LC. Pathophysiology of hypertension: what's new? Herz. 2006;31(4):294-302. doi: 10.1007/s00059-006-2821-y.
8. DiBona GF. Physiology in perspective: The wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289(3):R633-41. doi: 10.1152/ajpregu.00258.2005.
9. Vonend O, Okonek A, Stegbauer J, Habbel S, Quack I, Rump LC. Renovascular effects of sympathetic cotransmitters ATP and NPY are age-dependent in spontaneously hypertensive rats. Cardiovasc Res. 2005;66(2):345-52. doi: 10.1016/j.cardiores.2004.12.005.
10. Ishii M, Ikeda T, Takagi M, Sugimoto T, Atarashi K, Igari T, et al. Elevated plasma catecholamines in hypertensives with primary glomerular diseases. Hypertension. 1983;5(4):545-51.
11. • Converse Jr RL, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327(27):1912-8. doi: 10.1056/NEJM199212313272704. Important work about the sympathetic overactivity in patients with CKD.
12. Recordati G, Moss NG, Genovesi S, Rogenes P. Renal chemoreceptors. J Auton Nerv Syst. 1981;3(2-4):237-51.
13. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106(15):1974-9.
14. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57(4):846-51. doi: 10.1161/HYPERTENSIONAHA. 110.164780.
15. • Penne EL, Neumann J, Klein IH, Oey PL, Bots ML, Blankestijn PJ. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol. 2009;22(2):208-15. Important scientific statement regarding sympathetic hyperactivity in CKD.
16. Ditting T, Freisinger W, Siegel K, Fiedler C, Small L, Neuhuber W, et al. Tonic postganglionic sympathetic inhibition induced by afferent renal nerves? Hypertension. 2012;59(2):467-76. doi: 10.1161/HYPERTENSIONAHA.111.185538.
17. Bigazzi R, Kogosov E, Campese VM. Altered norepinephrine turnover in the brain of rats with chronic renal failure. J Am Soc Nephrol. 1994;4(11):1901-7.
18. Campese VM. Neurogenic factors and hypertension in chronic renal failure. J Nephrol. 1997;10(4):184-7.
19. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25(4 Pt 2):878-82.
20. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis. 1995;26(5):861-5.
21. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int. 1997;51(3):722-7.
22. Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens. 2002;15(8):717-24.
23. Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens. 1984;2(4):349-59.
24. Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens. 1998;11(6 Pt 1):723-8.
25. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol. 2001;12(11):2427-33.
26. Bernhardt WM, Wiesener MS, Weidemann A, Schmitt R, Weichert W, Lechler P, et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol. 2007;170(3):830-42. doi: 10.2353/ajpath.2007. 060455.
27. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20(5):933-9. doi: 10.1681/ASN.2008040402.
28. Lyson T, Ermel LD, Belshaw PJ, Alberg DG, Schreiber SL, Victor RG. Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling. Circ Res. 1993;73(3):596-602.
29. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262(6 Pt 1):E763-78.
30. Carlson SH, Wyss JM. Neurohormonal regulation of the sympathetic nervous system: new insights into central mechanisms of action. Curr Hypertens Rep. 2008;10(3):233-40.
31. Hering D, Zdrojewski Z, Krol E, Kara T, Kucharska W, Somers VK, et al. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. J Hypertens. 2007;25(1):157-61. doi: 10.1097/HJH.0b013e3280102d92.
32. Mallamaci F, Tripepi G, Maas R, Malatino L, Boger R, Zoccali C. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol. 2004;15(2):435-41.
33. Grassi G, Seravalle G, Ghiadoni L, Tripepi G, Bruno RM, Mancia G, et al. Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(11):2620-7. doi: 10.2215/CJN.06970711.
34. Bergamaschi CT, Campos RR, Lopes OU. Rostral ventrolateral medulla: A source of sympathetic activation in rats subjected to long-term treatment with L-NAME. Hypertension. 1999;34(4 Pt 2):744-7.
35. Hijmering ML, Stroes ES, Olijhoek J, Hutten BA, Blankestijn PJ, Rabelink TJ. Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol. 2002;39(4):683-8.
36. Augustyniak RA, Victor RG, Morgan DA, Zhang W. L-NAME- and ADMA-induced sympathetic neural activation in conscious rats. Am J Physiol Regul Integr Comp Physiol. 2006;290(3):R726-32. doi: 10.1152/ajpregu.00768.2004.
37. Zanzinger J. Role of nitric oxide in the neural control of cardiovascular function. Cardiovasc Res. 1999;43(3):639-49.
38. Zanzinger J, Czachurski J, Seller H. Neuronal nitric oxide reduces sympathetic excitability by modulation of central glutamate effects in pigs. Circ Res. 1997;80(4):565-71.
39. Sander M, Chavoshan B, Victor RG. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension. 1999;33(4):937-42.
40. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: A 3-year follow-up study. Circulation. 2000;102(13):1536-41.
41. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17(6):609-15. doi: 10.1097/MNH.0b013e328314b6ca.
42. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002;62(1):339-45. doi: 10.1046/j.1523-1755.2002.00437.x.
43. Shi B, Ni Z, Zhou W, Yu Z, Gu L, Mou S, et al. Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. Eur J Intern Med. 2010;21(5):444-8. doi: 10.1016/j.ejim.2010.07.001.
44. Campese VM, Ye S, Zhong H, Yanamadala V, Ye Z, Chiu J. Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol. 2004;287(2):H695-703. doi: 10.1152/ajpheart. 00619.2003.
45. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85-97. doi: 10.1161/ CIRCULATIONAHA.106.678342.
46. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol. 2003;14(2):425-30.
47. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005;115(5):1275-80. doi: 10.1172/JCI24066.
48. Li G, Xu J, Wang P, Velazquez H, Li Y, Wu Y, et al. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation. 2008;117(10):1277-82. doi: 10.1161/CIRCULATIONAHA.107.732032.
49. Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant. 2011;26(9):2930-4. doi: 10.1093/ndt/gfq857.
50. Cice G, Di Benedetto A, D'Isa S, D'Andrea A, Marcelli D, Gatti E, et al. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2010;56(21):1701-8. doi: 10.1016/j.jacc.2010.03.105.
51. Amann K, Koch A, Hofstetter J, Gross ML, Haas C, Orth SR, et al. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int. 2001;60(4):1309-23. doi: 10.1046/j.1523-1755. 2001.00936.x.
52. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438-44.
53. Tangri N, Shastri S, Tighiouart H, Beck GJ, Cheung AK, Eknoyan G, et al. beta-Blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study. Am J Kidney Dis. 2011;58(6):939-45. doi: 10.1053/j.ajkd.2011.06.024.
54. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70(11):1905-13. doi: 10.1038/sj.ki.5001835.
55. Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21(9):1709-17. doi: 10.1097/01.hjh.0000084733.53355.c3.
56. Siddiqi L, Joles JA, Oey PL, Blankestijn PJ. Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. J Hypertens. 2011;29(11):2176-80. doi: 10.1097/HJH.0b013e32834ae3c7.
57. Mahfoud F. [Renal denervation in hypertension - pro]. Dtsch Med Wochenschr. 2012;137(14):720. doi: 10.1055/s-0032-1304839.
58. • Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275-81. doi: 10.1016/S0140-6736(09)60566-3. First-in-man report of renal denervation in patients with resistant hypertension.
59. • Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903-9. doi: 10.1016/S0140-6736(10)62039-9. Randomized controlled trial investigating the effect of renal denervation versus medical treatment alone in patients with resistant hypertension.
60. Krum H, Barman N, Schlaich M, Sobotka P, Esler M, Mahfoud F, et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-7. doi: 10.1161/HYPERTENSIONAHA.110.163014.
61. • Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, et al. Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension. Hypertension. 2012. doi: 10.1161/HYPERTENSIONAHA.112.193870. Study showing that renal denervation reduces renal resistive indices and number of patients with micro- and macroalbuminuria, without impairing renal function.
62. Ott C, Janka R, Schmid A, Titze S, Ditting T, Sobotka PA, et al. Vascular and renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol. 2013. doi: 10.2215/CJN.08500812.
63. Ott C, Schmid A, Ditting T, Sobotka PA, Veelken R, Uder M, et al. Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research. J Clin Hypertens. 2012;14(11):799-801. doi: 10.1111/jch.12017.
64. • Schlaich MP, Bart B, Hering D, Walton A, Marusic P, Mahfoud F, et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol. 2013. doi: 10.1016/j.ijcard.2013.01.218. Important work about RDN in patients with ESRD.
65. Dörr O, Liebetrau C, Mollmann H, Achenbach S, Sedding D, Szardien S, et al. Renal sympathetic denervation does not aggravate functional or structural renal damage. J Am Coll Cardiol. 2012. doi: 10.1016/j.jacc.2012.09. 051.
66. Zilch O, Vos PF, Oey PL, Cramer MJ, Ligtenberg G, Koomans HA, et al. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. J Hypertens. 2007;25(6):1285-9. doi: 10.1097/HJH. 0b013e3280f9df85.
67. Friedman O, Bradley TD, Chan CT, Parkes R, Logan AG. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. Hypertension. 2010;56(6):1077-82. doi: 10.1161/HYPERTENSIONAHA. 110.154427.
68. Grassi G, Bertoli S, Seravalle G. Sympathetic nervous system: role in hypertension and in chronic kidney disease. Curr Opin Nephrol Hypertens. 2012;21(1):46-51. doi: 10.1097/MNH.0b013e32834db45d.